NEW YORK (GenomeWeb) – Becton Dickinson announced this week that it has agreed to sell 50.1 percent of its respiratory solutions business to funds advised by global private equity firm Apax Partners. The new company will include all business lines within BD's respiratory solutions business including respiratory diagnostics, and will have estimated annual revenue of approximately $900 million. BD will retain 49.9 percent of the company. The transaction values the entire business today at nearly $500 million, and is expected to close in late fiscal year 2016 or early fiscal year 2017.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

In a statement, National Institutes of Health Director Francis Collins says sexual harassment is "morally indefensible" and "unacceptable."

Octopuses might owe their intelligence to their liberal alterations to their genes, Cosmos reports.

Stat News and ProPublica report that African Americans are underrepresented in cancer clinical trials.

In Cell this week: genomic analysis of abdominal aortic aneurysm, effect of probiotics on the microbiome, and more.